Cover Image
Market Research Report

Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published by Transparency Market Research Product code 329312
Published Content info 189 Pages
Delivery time: 1-2 business days
Price
Back to Top
Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Published: April 10, 2019 Content info: 189 Pages
Description

Title:
Meningococcal Vaccines Market (Type - Polysaccharide Vaccines (Menomune, Mencevax, NmVac4), Conjugate Vaccines (Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, NmVac4-DT), Combination Vaccines (MenHibrix, Menitorix), Men B Vaccines (Bexsero, Trumenba); End use - Retail Pharmacies, Hospital Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Global Meningococcal Vaccines Market: Overview

This report analyzes the current and future scenario of the global meningococcal vaccines market. Advancements in healthcare, increase in awareness and education through various non-profit organizations, and a rise in patient awareness and health care expenditure are key factors that are projected to drive the global market during the forecast period.

The global meningococcal vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market.

Global Meningococcal vaccines Market: Key Segments

The global meningococcal vaccines market has been segmented based on type, end-user, and region. In terms of type, the global market has been classified into polysaccharide vaccines, conjugate vaccines, combination vaccines, and Men B vaccines. The polysaccharide vaccines segment has been further sub-segmented into Menomune, Mencevax, NmVac4, and others. The conjugate vaccines segment has been further sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, and NmVac4-DT. The combination vaccines segment has been further split into MenHibrix, and Menitorix. The Men B vaccines segment has been further sub-segmented into Bexsero, and Trumenba. Based on end-user, the market has been classified into retail pharmacies, hospital pharmacies, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Meningococcal vaccines Market: Regional Outlook

In terms of region, the global meningococcal vaccines market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles major players in the global meningococcal vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd.

The global meningococcal vaccines market has been segmented as below:

Global Meningococcal Vaccines Market, by Type

  • Polysaccharide Vaccines
    • Menomune
    • Mencevax
    • NmVac4
    • Others
  • Conjugate Vaccines
    • Menactra
    • Menveo
    • NeisVac-C
    • Nimenrix
    • Meningitec
    • Menjugate
    • MenAfriVac
    • NmVac4-DT
  • Combination Vaccines
    • MenHibrix
    • Menitorix
    • Men B Vaccines
    • Bexsero
    • Trumenba

Global Meningococcal Vaccines Market, by End-user

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

Global Meningococcal Vaccines Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Table of Contents

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Meningococcal Vaccines Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
    • 4.3.4. Market Trends
  • 4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2016-2026
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1.Pipeline Analysis
  • 5.2. Epidemiology Of Meningococcal Disease
  • 5.3. Regulatory Scenario.

6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 6.3.1. Polysaccharide
      • 6.3.1.1. Menomune
      • 6.3.1.2. Mencevax
      • 6.3.1.3. NmVac4
      • 6.3.1.4. Others
    • 6.3.2. Conjugate Vaccines
      • 6.3.2.1. Menactra
      • 6.3.2.2. Menveo
      • 6.3.2.3. NeisVac-C
      • 6.3.2.4. Nimenrix
      • 6.3.2.5. Meningitec
      • 6.3.2.6. Menjugate
      • 6.3.2.7. MenAfriVac
      • 6.3.2.8. NmVac4-DT
    • 6.3.3. Combination Vaccines
      • 6.3.3.1. MenHibrix
      • 6.3.3.2. Menitorix
    • 6.3.4. Men B Vaccines
      • 6.3.4.1. Bexsero
      • 6.3.4.2. Trumenba
    • 6.3.5. Others

7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Others
  • 7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user

8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region/Sub-Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia-Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Meningococcal Vaccines Market Attractiveness, by Region/Sub-Region

9. North America Meningococcal Vaccines Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
    • 9.1.1. Key Findings
  • 9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 9.2.1. Polysaccharide
      • 9.2.1.1. Menomune
      • 9.2.1.2. Mencevax
      • 9.2.1.3. NmVac4
      • 9.2.1.4. Others
    • 9.2.2. Conjugate Vaccines
      • 9.2.2.1. Menactra
      • 9.2.2.2. Menveo
      • 9.2.2.3. NeisVac-C
      • 9.2.2.4. Nimenrix
      • 9.2.2.5. Meningitec
      • 9.2.2.6. Menjugate
      • 9.2.2.7. MenAfriVac
      • 9.2.2.8. NmVac4-DT
    • 9.2.3. Combination Vaccines
      • 9.2.3.1. MenHibrix
      • 9.2.3.2. Menitorix
    • 9.2.4. Men B Vaccines
      • 9.2.4.1. Bexsero
      • 9.2.4.2. Trumenba
    • 9.2.5. Others
  • 9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Others
  • 9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2016-2026
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
    • 9.5.1. By Type
    • 9.5.2. By End-user
    • 9.5.3. By Country

10. Europe Meningococcal Vaccines Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 10.2.1. Polysaccharide
      • 10.2.1.1. Menomune
      • 10.2.1.2. Mencevax
      • 10.2.1.3. NmVac4
      • 10.2.1.4. Others
    • 10.2.2. Conjugate Vaccines
      • 10.2.2.1. Menactra
      • 10.2.2.2. Menveo
      • 10.2.2.3. NeisVac-C
      • 10.2.2.4. Nimenrix
      • 10.2.2.5. Meningitec
      • 10.2.2.6. Menjugate
      • 10.2.2.7. MenAfriVac
      • 10.2.2.8. NmVac4-DT
    • 10.2.3. Combination Vaccines
      • 10.2.3.1. MenHibrix
      • 10.2.3.2. Menitorix
    • 10.2.4. Men B Vaccines
      • 10.2.4.1. Bexsero
      • 10.2.4.2. Trumenba
    • 10.2.5. Others
  • 10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 10.3.1. Retail Pharmacies
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Others
  • 10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
    • 10.4.1. Germany
    • 10.4.2. UK
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
    • 10.5.1. By Type
    • 10.5.2. By End-user
    • 10.5.3. By Country/Sub-Region

11. Asia-Pacific Meningococcal Vaccines Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 11.2.1. Polysaccharide
      • 11.2.1.1. Menomune
      • 11.2.1.2. Mencevax
      • 11.2.1.3. NmVac4
      • 11.2.1.4. Others
    • 11.2.2. Conjugate Vaccines
      • 11.2.2.1. Menactra
      • 11.2.2.2. Menveo
      • 11.2.2.3. NeisVac-C
      • 11.2.2.4. Nimenrix
      • 11.2.2.5. Meningitec
      • 11.2.2.6. Menjugate
      • 11.2.2.7. MenAfriVac
      • 11.2.2.8. NmVac4-DT
    • 11.2.3. Combination Vaccines
      • 11.2.3.1. MenHibrix
      • 11.2.3.2. Menitorix
    • 11.2.4. Men B Vaccines
      • 11.2.4.1. Bexsero
      • 11.2.4.2. Trumenba
    • 11.2.5. Others
  • 11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 11.3.1. Retail Pharmacies
    • 11.3.2. Hospital Pharmacies
    • 11.3.3. Others
  • 11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
    • 11.4.1. Japan
    • 11.4.2. China
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia-Pacific
  • 11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
    • 11.5.1. By Type
    • 11.5.2. By End-user
    • 11.5.3. By Country/Sub-Region

12. Latin America Meningococcal Vaccines Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 12.2.1. Polysaccharide
      • 12.2.1.1. Menomune
      • 12.2.1.2. Mencevax
      • 12.2.1.3. NmVac4
      • 12.2.1.4. Others
    • 12.2.2. Conjugate Vaccines
      • 12.2.2.1. Menactra
      • 12.2.2.2. Menveo
      • 12.2.2.3. NeisVac-C
      • 12.2.2.4. Nimenrix
      • 12.2.2.5. Meningitec
      • 12.2.2.6. Menjugate
      • 12.2.2.7. MenAfriVac
      • 12.2.2.8. NmVac4-DT
    • 12.2.3. Combination Vaccines
      • 12.2.3.1. MenHibrix
      • 12.2.3.2. Menitorix
    • 12.2.4. Men B Vaccines
      • 12.2.4.1. Bexsero
      • 12.2.4.2. Trumenba
    • 12.2.5. Others
  • 12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 12.3.1. Retail Pharmacies
    • 12.3.2. Hospital Pharmacies
    • 12.3.3. Others
  • 12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Type
    • 12.5.2. By End-user
    • 12.5.3. By Country/Sub-Region

13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
    • 13.2.1. Polysaccharide
      • 13.2.1.1. Menomune
      • 13.2.1.2. Mencevax
      • 13.2.1.3. NmVac4
      • 13.2.1.4. Others
    • 13.2.2. Conjugate Vaccines
      • 13.2.2.1. Menactra
      • 13.2.2.2. Menveo
      • 13.2.2.3. NeisVac-C
      • 13.2.2.4. Nimenrix
      • 13.2.2.5. Meningitec
      • 13.2.2.6. Menjugate
      • 13.2.2.7. MenAfriVac
      • 13.2.2.8. NmVac4-DT
    • 13.2.3. Combination Vaccines
      • 13.2.3.1. MenHibrix
      • 13.2.3.2. Menitorix
    • 13.2.4. Men B Vaccines
      • 13.2.4.1. Bexsero
      • 13.2.4.2. Trumenba
    • 13.2.5. Others
  • 13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
    • 13.3.1. Retail Pharmacies
    • 13.3.2. Hospital Pharmacies
    • 13.3.3. Others
  • 13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
    • 13.4.1. GCC Countries
    • 13.4.2. Israel
    • 13.4.3. South Africa
    • 13.4.4. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
    • 13.5.1. By Type
    • 13.5.2. By End-user
    • 13.5.3. By Country/Sub-Region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Competitive Business Strategies
  • 14.3. Company Profiles
    • 14.3.1. Neuron Biotech
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Overview
      • 14.3.1.3. Product Portfolio
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Baxter international
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Overview
      • 14.3.2.3. Product Portfolio
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Pfizer Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Overview
      • 14.3.3.3. Product Portfolio
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Novartis International
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Overview
      • 14.3.4.3. Product Portfolio
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Sanofi S.A
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Overview
      • 14.3.5.3. Product Portfolio
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. JN-International Medical Corporation
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Overview
      • 14.3.6.3. Product Portfolio
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Biomed Pvt. Ltd.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Overview
      • 14.3.7.3. Product Portfolio
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Serum Institute of India Ltd
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Overview
      • 14.3.8.3. Product Portfolio
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline plc
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Overview
      • 14.3.9.3. Product Portfolio
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
  • Table 01 Global Meningococcal Vaccine Market Pipeline Analysis
  • Table 02 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 03 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 04 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 05 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 06 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 07 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 08 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Region, 2016-2026
  • Table 09 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country, 2016-2026
  • Table 10 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 11 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 12 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 13 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 14 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 15 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 16 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 17 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 18 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 19 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 20 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 21 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 22 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 23 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 24 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 25 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 26 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 27 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 28 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 29 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 30 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 31 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 32 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 33 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 34 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 35 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 36 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Table 37 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 38 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Type, 2016-2026
  • Table 39 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Polysaccharide Vaccines, 2016-2026
  • Table 40 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Conjugate Vaccines, 2016-2026
  • Table 41 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Combination Vaccines, 2016-2026
  • Table 42 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by Men B Vaccines, 2016-2026
  • Table 43 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, by End-user, 2016-2026
  • Figure 01 Global Meningococcal Vaccines Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
  • Figure 02 Market Snapshot of Global Meningococcal Vaccines Market
  • Figure 03 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 04 Market Value Share, by Type, 2017
  • Figure 05 Market Value Share, by End-user, 2017
  • Figure 06 Market Value Share, by Region, 2017
  • Figure 07 Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2017 and 2026
  • Figure 08 Global Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 09 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Polysaccharide Vaccines, 2016-2026
  • Figure 10 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2016-2026
  • Figure 11 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2016-2026
  • Figure 12 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2016-2026
  • Figure 13 Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2017 and 2026
  • Figure 14 Global Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 15 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2016-2026
  • Figure 16 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2016-2026
  • Figure 17 Global Meningococcal Vaccines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2016-2026
  • Figure 18 Global Meningococcal Vaccines Market Value Share (%), by Region, 2017 and 2026
  • Figure 19 Global Meningococcal Vaccines Market Attractiveness, by Region, 2018-2026
  • Figure 20 North America Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 21 North America Meningococcal Vaccines Market Value Share (%), by Country, 2017 and 2026
  • Figure 22 North America Meningococcal Vaccines Market Attractiveness, by Country, 2018-2026
  • Figure 23 North America Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
  • Figure 24 North America Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 25 North America Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
  • Figure 26 North America Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 27 Europe Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 28 Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 29 Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 30 Europe Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
  • Figure 31 Europe Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 32 Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
  • Figure 33 Europe Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 34 Asia Pacific Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 35 Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 36 Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 37 Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
  • Figure 38 Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 39 Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
  • Figure 40 Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 41 Latin America Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 42 Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 43 Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 44 Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
  • Figure 45 Latin America Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 46 Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
  • Figure 47 Latin America Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 48 Middle East & Africa Meningococcal Vaccines Market Value (US$ Mn) Forecast, 2016-2026
  • Figure 49 Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2017 and 2026
  • Figure 50 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region, 2018-2026
  • Figure 51 Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2017 and 2026
  • Figure 52 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type, 2018-2026
  • Figure 53Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2017 and 2026
  • Figure 54 Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user, 2018-2026
  • Figure 55 Global Meningococcal Vaccines Market Share, by Company, 2018
  • Figure 56 Baxter International, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 57 Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018
  • Figure 58 Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 59 Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018
  • Figure 60 Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
  • Figure 61 Novartis AG Breakdown of Net Sales, by Region, 2017
  • Figure 62 Novartis AG Breakdown of Net Sales, by Business Segment, 2017
  • Figure 63 Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2017
  • Figure 64 Sanofi S.A Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 65 Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2017
  • Figure 66 GlaxoSmithKline plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2017
  • Figure 67 GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
Back to Top